ADIPOQ and Alzheimer disease: In the severe AD group, repeated measurements of serum adiponectin level in response to dupilumab treatment (baseline, week 16, and week 52) indicated no significant changes (p = 0.18) while the EASI score decreased significantly using repeated-measures ANOVA.